证券代码：300347 证券简称：泰格医药 公告编码（2023）021号 杭州泰格医药科技股份有限公司 关于参加浙江辖区上市公司 2023 年投资者 网上集体接待日活动的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者重 大遗漏负连带责任。 为进一步加强与投资者的互动交流，杭州泰格医药科技股份有限公司（以下简称"公 司"）将参加由浙江证监局、浙江省上市公司协会与深圳市全景网络有限公司联合举办的 "2023年浙江辖区上市公司投资者集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录 "全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演APP，参与本次互 动交流，活动时间为2023年5月12日（周五）15：00-17：00。届时公司高管将在线就公司 2022年度业绩、公司治理、发展战略、经营状况、融资计划、股权激励和可持续发展等投 资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 杭州泰格医药科技股份有限公司董事会 二〇二三年五月八日 ...

Financial Performance - In 2022, the company's revenue increased by 35.9% year-on-year, reaching RMB 7,085.5 million, up from RMB 5,213.5 million in 2021[5]. - Gross profit for 2022 was RMB 2,785.4 million, up 23.9% from RMB 2,248.1 million in 2021[12]. - Net profit attributable to the company's owners decreased by 30.0% to RMB 2,016.1 million from RMB 2,879.1 million in 2021[12]. - Revenue for the year ended December 31, 2022, was RMB 7,085.5 million, representing a 35.9% increase from RMB 5,213.5 million in 2021[12]. - The company secured new orders amounting to RMB 9,673.4 million in 2022, slightly up from RMB 9,645.5 million in the previous year[18]. - The future contracted revenue as of December 31, 2022, was RMB 13,785.9 million, reflecting a year-on-year increase of 20.9%[19]. - The adjusted net profit attributable to the company's owners decreased by 30.0% year-on-year to RMB 2,016.1 million, compared to RMB 2,879.1 million in the same period last year[64]. - The net profit for the year decreased by 32.8% year-on-year to RMB 2,281.3 million, down from RMB 3,396.6 million in the same period last year[64]. Revenue Breakdown - Revenue from clinical trial technical services amounted to RMB 4,125.2 million, while revenue from clinical trial-related services and laboratory services reached RMB 2,960.3 million, reflecting year-on-year growth of 37.8% and 33.4% respectively[5]. - Revenue generated in China grew by 30.7% year-on-year to RMB 3,601.6 million, while overseas revenue increased by 41.8% to RMB 3,483.9 million[5]. - Revenue from clinical trial-related services and laboratory services increased by 33.4% year-on-year to RMB 2,960.3 million, up from RMB 2,219.9 million in the same period last year[41]. Project and Service Expansion - The number of ongoing drug clinical research projects increased from 567 as of December 31, 2021, to 680 as of December 31, 2022[6]. - The company signed 21 new multi-regional clinical trial projects during the reporting period, increasing ongoing multi-regional clinical trials from 50 to 62[8]. - The number of ongoing single-region clinical trials rose from 132 to 188, while multi-region trials increased from 50 to 62 during the same period[22]. - The company established 189 clinical trial excellence centers and 100 green channel centers in China by December 31, 2022[8]. - The company expanded its global presence by establishing new subsidiaries in the UK, Netherlands, and Argentina, totaling 29 subsidiaries across five continents[20]. Investment and Acquisitions - The company completed the acquisition of European contract research organization Marti Farm D.o.o. in January 2023, enhancing local regulatory expertise in Europe[8]. - The company completed the acquisition of Experimur LLC for a total cash consideration of up to $76 million, which has been integrated into the company's consolidated financial statements[106]. - The company acquired 100% of Meditip Co., Ltd for a cash consideration of 20,091,556,000 KRW (approximately RMB 105.4 million), enhancing its market research capabilities in the biopharmaceutical sector[110]. - The company approved the acquisition of 88.1% of Frontage Clinical for approximately $13.215 million, which will be consolidated into the company's financial statements[118]. Workforce and Talent Management - The number of employees increased from 8,326 to 9,233, reflecting a growth in workforce[26]. - The company has recruited over 560 interns for clinical trial-related positions during the reporting period, collaborating with over 23 universities to attract high-quality graduates[101]. - The company has implemented a competitive compensation package, including long-term equity incentive plans, to enhance its competitive advantage and talent retention[102]. - The company faces a risk of talent loss, as the competition for qualified personnel is intense, which could significantly impact its competitiveness and financial performance[150]. Corporate Governance - The board consists of seven members, including four executive directors and three independent non-executive directors[157]. - The company emphasizes the importance of independent directors in ensuring corporate governance and strategic oversight[165]. - The company has adopted corporate governance practices in line with the principles outlined in the listing rules, maintaining high standards of governance throughout the reporting period[177]. - The audit committee, composed of three independent non-executive directors, held three meetings during the reporting period to review financial performance and internal controls[199]. Market Trends and Challenges - The global contract research organization (CRO) market size increased from $52.54 billion in 2017 to $75.94 billion in 2021, with a compound annual growth rate (CAGR) of 9.7%[123]. - The company anticipates continued business development and expansion, necessitating significant management, financial, and human resources to enhance services and technology[142]. - Increased competition in the global pharmaceutical contract research market may lead to pricing pressure, potentially reducing revenue and profitability[140]. - The regulatory environment in China is increasingly stringent, driving demand for emerging business services related to drug lifecycle management[131]. Strategic Goals and Future Outlook - The company aims to create lasting value for all stakeholders despite global macroeconomic challenges and the impact of the pandemic[5]. - The company plans to continue increasing R&D investment in response to growing market demand for innovative drugs and medical devices[123]. - The company aims to optimize services to meet the evolving needs of clients, supported by its growing and diversified customer base[103]. - The company is committed to investing in innovative biopharmaceutical and medical device startups, aiming to build long-term partnerships and promote industry innovation[104].

Financial Performance - Revenue for Q1 2023 was RMB 1,804.57 million, a slight decrease of 0.73% compared to the same period last year[3] - Net profit attributable to shareholders increased by 9.65% to RMB 568.46 million in Q1 2023[3] - Total revenue for the first quarter of 2023 was 1,804,571,375.28 RMB, a slight decrease from 1,817,858,958.69 RMB in the same period last year[16] - Operating profit for the first quarter of 2023 was 630,897,782.90 RMB, compared to 654,381,329.25 RMB in the same period last year[17] - Net profit for the first quarter of 2023 was 568,325,660.27 RMB, slightly down from 573,970,498.59 RMB in the same period last year[17] - Net profit attributable to parent company owners increased to 568.46 million yuan, up 9.66% from 518.42 million yuan in the previous period[18] - Comprehensive income totaled 521.77 million yuan, down 8.69% from 571.45 million yuan in the previous period[18] - Basic earnings per share increased to 0.66 yuan, up 10% from 0.60 yuan in the previous period[18] - Revenue from sales of goods and services decreased to 1.53 billion yuan, down 13.16% from 1.76 billion yuan in the previous period[19] Cash Flow - Operating cash flow decreased significantly by 90.59% to RMB 28.51 million due to reduced large project payments and increased operating expenses[9] - Investment cash flow improved by 57.74% to a net outflow of RMB 547.51 million, as there were no significant acquisition payments compared to the previous year[9] - Cash flow from operating activities decreased to 28.51 million yuan, down 90.59% from 303.08 million yuan in the previous period[20] - Cash flow from investing activities improved to -547.51 million yuan, compared to -1.30 billion yuan in the previous period[20] - Cash flow from financing activities decreased to 302.16 million yuan, down 43.34% from 533.08 million yuan in the previous period[20] - Cash and cash equivalents at the end of the period stood at 7.55 billion yuan, down 4.59% from 7.92 billion yuan in the previous period[21] - Cash paid for employee compensation increased to 788.73 million yuan, up 16.37% from 677.79 million yuan in the previous period[20] - Cash received from tax refunds increased to 3.13 million yuan, up 427.47% from 593,915.44 yuan in the previous period[20] Assets and Liabilities - The company's total assets grew by 2.64% to RMB 28.17 billion as of the end of Q1 2023[3] - Total assets at the end of the period amount to 28,172,127,699.99 yuan[14] - Total liabilities for the first quarter of 2023 were 4,853,582,844.27 RMB, compared to 4,765,479,654.95 RMB in the same period last year[15] - Total equity for the first quarter of 2023 was 23,318,544,855.72 RMB, up from 22,681,030,941.49 RMB in the same period last year[15] - Contract liabilities for the first quarter of 2023 were 870,900,929.39 RMB, down from 911,073,826.39 RMB in the same period last year[15] - Employee compensation payable for the first quarter of 2023 was 170,191,493.18 RMB, down from 292,868,161.24 RMB in the same period last year[15] - Taxes payable for the first quarter of 2023 were 180,537,915.05 RMB, down from 197,737,378.83 RMB in the same period last year[15] - Long-term loans for the first quarter of 2023 were 280,710,389.80 RMB, up from 244,641,137.61 RMB in the same period last year[15] - Lease liabilities for the first quarter of 2023 were 466,590,632.04 RMB, down from 488,975,554.75 RMB in the same period last year[15] - Monetary funds at the end of the period amount to 7,616,130,648.84 yuan[14] - Accounts receivable at the end of the period amount to 1,077,375,173.77 yuan[14] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 40,921[10] - Ye Xiaoping holds 20.32% of the shares, totaling 177,239,541 shares[10] - HKSCC NOMINEES LIMITED holds 14.11% of the shares, totaling 123,119,379 shares[10] - Hong Kong Securities Clearing Company Limited holds 9.26% of the shares, totaling 80,821,415 shares[10] - Cao Xiaochun holds 5.92% of the shares, totaling 51,661,774 shares[10] - Industrial and Commercial Bank of China - China Europe Medical Health Hybrid Securities Investment Fund holds 4.20% of the shares, totaling 36,652,574 shares[10] - TEMASEK FULLERTON ALPHA PTE LTD holds 2.23% of the shares, totaling 19,469,370 shares[10] Clinical Trial Services - Clinical trial technical service revenue declined slightly due to a reduction in multi-regional clinical trial business, particularly vaccine-related trials[6] - Clinical trial-related services and laboratory service revenue increased, driven by growth in data management, statistical analysis, and patient recruitment services[6] Financial Metrics - Fair value change gains increased by 40.98% to RMB 176.41 million, mainly due to gains from other non-current financial assets[8] - Financial expenses decreased by 47.37% to RMB -15.96 million, primarily due to reduced interest expenses[8] - The company's weighted average return on equity (ROE) slightly increased by 0.03 percentage points to 2.86%[3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347） 2023年第一季度報告 本公告根據香港聯合交易所有限公司證券上市規則第13.09(2)條和第13.10B條及 香港法例第571章《證券及期貨條例》第XIVA部內幕消息條文作出。 下文為杭州泰格醫藥科技股份有限公司（「本公司」，連同其子公司統稱「本集團」） 2023年財政年度第一季度報告。本公告及隨附的財務報表最初以中文編製，並以 中英文版本刊登。如中英文版本有任何歧義或衝突，概以中文版本為準。 謹請本公司股東及公眾投資者注意，隨附財務報表乃根據中國企業會計準則編製 且未經審計。 承董事會命 杭州泰格醫藥科技股份有限公司 葉小平 董事長 ...

Financial Performance - Tigermed reported a total revenue of RMB 3.5 billion in 2022, representing a year-over-year growth of 25%[19]. - The company achieved a net profit of RMB 600 million, which is an increase of 30% compared to the previous year[19]. - The company's operating revenue for 2022 was CNY 7,085,471,468.87, representing a 35.91% increase compared to CNY 5,213,538,054.00 in 2021[27]. - The net profit attributable to shareholders decreased by 30.19% to CNY 2,006,552,035.30 in 2022 from CNY 2,874,163,020.17 in 2021[27]. - The net profit after deducting non-recurring gains and losses increased by 25.01% to CNY 1,539,519,788.35 in 2022[27]. - The total assets at the end of 2022 were CNY 27,446,510,596.44, a 15.61% increase from CNY 23,741,171,551.32 at the end of 2021[27]. - The basic earnings per share decreased by 29.91% to CNY 2.32 in 2022 from CNY 3.31 in 2021[27]. - The cash flow from operating activities for 2022 was CNY 1,357,500,892.41, a decrease of 4.66% from CNY 1,423,796,250.17 in 2021[27]. - The company's weighted average return on equity decreased to 10.72% in 2022 from 16.75% in 2021[27]. - The company reported a significant increase in financial assets, with total financial assets reaching ¥9,992,662,244.60, reflecting a growth in investment activities[107]. Strategic Focus and Growth - The report outlines the company's strategic focus on expanding its market presence and enhancing its service offerings through new technologies and products[8]. - The management discussion highlights the company's growth trajectory and future outlook, indicating a positive trend in revenue generation[8]. - Tigermed plans to expand its market presence in Southeast Asia, targeting a 20% increase in market share by 2024[19]. - The company is actively pursuing opportunities for mergers and acquisitions to bolster its competitive position in the market[8]. - The company aims to leverage its extensive network and partnerships to drive innovation in drug development and clinical trials[8]. - The company is investing RMB 200 million in new product development, focusing on digital health technologies[19]. - The company is exploring partnerships with biotech firms to enhance its service offerings and expand its portfolio[19]. - The company aims to continue selective acquisitions and investments for growth, but failure to identify suitable targets may hinder expected returns[127]. Compliance and Governance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present for the report's approval[4]. - The company strictly adheres to legal and regulatory requirements for corporate governance, ensuring transparency and fairness in shareholder meetings[133]. - The company has established an audit committee to oversee internal and external audits, ensuring the authenticity and completeness of financial information[136]. - The company has maintained independence from its controlling shareholders in terms of operations, assets, and financial management[137]. - The company has a dedicated investor relations management system to enhance communication and transparency with investors[135]. - The company has implemented a business continuity plan to mitigate risks from unforeseen events, including natural disasters and pandemics[119]. Social Responsibility and Sustainability - The report details the company's commitment to social responsibility and environmental sustainability initiatives[8]. - The company received the highest AAA rating in the ESG rating from the Shenzhen Stock Exchange in July 2022[69]. - The company has implemented measures to reduce carbon emissions, although specific details were not provided[193]. - There were no administrative penalties due to environmental issues during the reporting period[193]. Employee and Management - The company has a total of 11 board meetings held during the reporting period, with all directors present at least once[157]. - The company’s total employee count increased from 8,326 to 9,233, reflecting growth in operational capacity[84]. - The company has implemented employee stock ownership plans and restricted stock incentive plans in 2017, 2019, 2020, and 2022 to retain talent[166]. - The company has conducted extensive employee training programs focusing on quality and compliance to enhance employee skills and organizational performance[167]. - The company is focused on maintaining a stable management team amidst personnel changes[143]. - The company has a strong management team with diverse backgrounds in pharmaceuticals, including ZHUAN YIN, who has unique experience in drug review, particularly in oncology[144]. Market Trends and Challenges - The global CRO market is projected to grow at a compound annual growth rate (CAGR) of 10.8%, reaching USD 126.99 billion by 2026[40]. - The clinical CRO market is expected to reach USD 78.04 billion by 2026, growing at a CAGR of 9.2%[40]. - The demand for reliable CRO services is increasing due to the complexity and high costs associated with new drug development, driving the need for integrated and innovative solutions[47]. - The company faces increasing competition from multinational CROs and domestic small and medium-sized CROs, which may lead to pricing pressure and reduced revenue and profitability[121]. - The company is facing uncertainties related to potential future disruptions that could adversely affect its business operations and financial performance[119]. - The demand for biopharmaceutical research and development services is at risk of decline due to potential slowdowns in the global pharmaceutical market and reduced outsourcing willingness from clients[120]. Financial Management and Investments - The company is actively pursuing new investment opportunities, including significant equity investments and ongoing non-equity investments[110]. - The company reported a net profit impact of ¥53,585,730 from fair value changes and ¥10,275,070 from investment income[99]. - The company has no current foreign currency hedging policy but will monitor foreign exchange risks and consider hedging when necessary[130]. - The company reported restricted assets totaling ¥54,194,256.65 in fixed deposits, indicating liquidity constraints[108]. - The company has established multiple subsidiaries, including Tigermed UK LTD and Tigermed Poland SP. Z O.O., with no significant impact on overall operations[118]. Clinical Research and Development - The company has developed a digital clinical trial platform, "Tailing Research," which includes various systems for clinical research management and risk-based quality management[48]. - The company launched the RBQM system (Phase II) in September 2022, focusing on data analysis and risk visualization for centralized monitoring[49]. - The company established a Decentralized Clinical Trial (DCT) department in early 2023 to develop and implement remote and intelligent clinical trial services[49]. - The company has successfully assisted in the approval of 4 COVID-19 vaccine products for emergency use in China and overseas during the reporting period[63]. - The company has maintained a market-leading position in China's clinical CRO industry, providing professional services for 65% of the new drug approvals in China since 2004[63].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347） 截至2022年12月31日止年度之 年度業績公告 財務摘要 截至12月31日止年度 2022年 2021年 變動(2) 人民幣百萬元 人民幣百萬元 經營業績 收入 7,085.5 5,213.5 35.9% 毛利 2,785.4 2,248.1 23.9% 本公司擁有人應佔淨利潤 2,016.1 2,879.1 (30.0)% 本公司擁有人應佔經調整淨利潤(1) 1,665.8 1,585.3 5.1% 盈利能力 毛利率 39.3% 43.1% (3.8)% 本公司擁有人應佔淨利潤率 28.5% 55.2% (26.7)% 本公司擁有人應佔經調整淨利潤率(1) 23.5% 30.4% (6.9)% ...